| Covance Reports First Quarter Revenue of $482M and EPS of $0.60; Updates Full Year Financial Targets (PR Newswire) Covance Inc. Â today reported earnings for its first quarter ended March 31, 2010 of $0.60 per diluted share versus $0.63 per diluted share in the first quarter of 2009. us.rd.yahoo.com |
Employers Race for Retiree Funds Some employers worry a $5 billion federal fund created under the health care overhaul bill and intended to help offset the costs of providing health care for early retirees will be exhausted quickly. online.wsj.com |
ERT to Present at The BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5, 2010 (PR Newswire) ERT , announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive Vice President and CFO, are scheduled to present at The BMO Capital Markets 10th Annual Focus on Healthcare Conference at 3:00 PM ET on August 5, 2010 in New York. us.rd.yahoo.com |
Axial Capital Can't Get Enough of QLT Market Folly submits:Hedge fund Axial Capital Management seems to have an insatiable appetite for shares of QLT Inc (QLTI) at current levels. Eliav Assouline and Marc Andersen's hedge fund firm has made the following acquisitions according to multiple SEC Form 4 filings:August 26th: 50,000 shares @ $5.67August 27th: 50,000 shares @ $5.78August 30th: 7,400 shares @ $5.70August 31st: 60,506 shares @ $5.75September 1st: 5,318 shares @ $5.75Complete Story » seekingalpha.com |
Vivus Races to Capture U.S. Approval of Obesity Drug The Burrill Report submits: By Michael FitzhughShed weight. Keep it off. That's the promise of the experimental weight loss drug Qnexa, according to its developer, Vivus (VVUS). Patients taking the biggest dose of Qnexa in a recent trial achieved and maintained an average loss of 26 pounds over two years with minimal side-effects, the California company says. Illustrating Qnexa’s safety and efficacy to the U.S. Food and Drug Administration is Vivus’ top concern as it races to dispel concerns about the drug’s risks and capture the first U.S. approval for a new weight loss drug in a decade. Complete Story » seekingalpha.com |